Acerta Pharma B.V. (Acerta), a clinical-stage biopharmaceutical company,
announced today that it has entered into a definitive agreement with
AstraZeneca AZN whereby AstraZeneca will acquire a majority stake in Acerta.
The transaction provides AstraZeneca with Acerta's potential
best-in-class irreversible oral Bruton's tyrosine kinase (Btk)
inhibitor, acalabrutinib (ACP-196), currently in Phase III development
for B-cell blood cancers and in Phase I/II clinical trials in multiple
solid tumors.
"We are excited to announce this strategic transaction with AstraZeneca,
which is a testament to the value inherent in Acerta and acalabrutinib,"
said David Johnson, Chief Executive Officer of Acerta. "AstraZeneca
brings tremendous expertise and resources that will help us maximize the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in